Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

17.99 -3.97 (-18.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,737,817
Open 20.04
Bid (Size) 17.18 (2)
Ask (Size) 17.98 (1)
Prev. Close 21.96
Today's Range 16.86 - 20.06
52wk Range 15.99 - 29.30
Shares Outstanding 90,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga

Performance

YTD
-5.32%
-5.32%
1 Month
-31.93%
-31.93%
3 Month
-30.38%
-30.38%
6 Month
-9.91%
-9.91%
1 Year
+5.70%
+5.70%

More News

Read More
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
Via Benzinga
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Analyst Expectations For Myriad Genetics's Future
Via Benzinga
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Myriad Genetics to Host Investor Event on October 9, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Via Investor's Business Daily
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Avantor Stock Earns 84 RS Rating
Via Investor's Business Daily
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.